Premium
Serum β 2 ‐microglobulin in malignant lymphoma
Author(s) -
Hagberg H.,
Killander A.,
Simonsson B.
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830615)51:12<2220::aid-cncr2820511212>3.0.co;2-a
Subject(s) - medicine , beta 2 microglobulin , malignant lymphoma , lymphoma , oncology , pathology
Serum β2‐microglobulin (S‐β 2 m) was measured at diagnosis in 189 patients with malignant lymphoma, all with a normal serum creatinine clearance. The diagnosis was non‐Hodgkin's lymphoma (NHL) in 149 patients and Hodgkin's disease (HD) in 40. Among the NHL group, S‐β 2 m was raised (>3.0 mg/1) in 15% of patients with Stage I and II and in 65% of those with Stage III and IV. The corresponding frequencies for HD were 11% and 83% respectively. In NHL, a high pretreatment level of S‐β 2 m was found to be a poor prognostic sign in all stages. Patients in Stage I and II with an elevated pretreatment level of S‐β 2 m had a higher relapse rate than those with normal S‐β2m. In Stage III and IV patients with initial levels > 3.5 mg/l, the survival was significantly shorter than in those with initial values of <3.5 mg/l. A lower mean S‐β 2 m value was found in Stage III and IV patients who achieved complete remission than in those who did not. Serial determinations of S‐β 2 m in 23 patients with NHL showed that increased pretreatment levels became normal when remission was achieved and increased again in relapse. Thus the S‐β 2 m provides valuable prognostic information in this group of patients.